Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL
Clinical trial NCT07569965 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07569965
- Sponsor
- Miltenyi Biomedicine GmbH
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2029-09-01
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.